

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EMBRY HOLDINGS LIMITED**

**安莉芳控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1388)**

### **ANNOUNCEMENT COMPLIANCE WITH RULES 13.51B(2) AND 13.51(2)(N) OF THE LISTING RULES**

This announcement is made by Embry Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51B(2) and 13.51(2)(n) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to the change of particulars of Mr. Lau Siu Ki (“**Mr. Lau**”), an independent non-executive director (the “**Director(s)**”) of the Company and the chairman of the audit committee of the board of Directors.

Reference is made to the announcement (the “**Announcement**”) of the Company dated 5 November 2019 in relation to the Market Misconduct Tribunal (the “**MMT**”) Proceedings of China Medical & Healthcare Group Limited (formerly known as COL Capital Limited) (stock code: 383) (“**COL**”), a company listed on the Stock Exchange, in which Mr. Lau was a former independent non-executive director. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless otherwise stated.

On 12 May 2021, the Securities and Futures Commission (the “**SFC**”) issued a press release, in relation to a decision of the MMT against COL and its former and current directors for failing to disclose inside information as soon as reasonably practicable. The MMT fined COL, and six of its former and current directors, including Mr. Lau, who was then serving as the independent non-executive director of COL at the material time a total of HK\$4.2 million. Pursuant to the MMT’s order, Mr. Lau shall attend an SFC-approved training programme on the corporate disclosure regime, directors’ duties and corporate governance. For details, please refer to the press release published on the website of the SFC.

Mr. Lau was a former independent non-executive director of COL and resigned all duties in COL in December 2018. Mr. Lau is an independent non-executive Director, and is not involved in the daily operation of our Company. To the knowledge and information of the Board, the disciplinary action is unrelated to Directors or senior management members of the Company or any business, financial condition or operations of the Group (except for the fact that Mr. Lau is an independent non-executive Director), and will have no material adverse impact on the Group. After due and careful consideration, the Board (other than Mr. Lau) considers that the background, expertise, skills, experience and independence of Mr. Lau can facilitate the decision-making ability of the Board, and is beneficial to the development and management of each business of the Group, and that to the knowledge of the Company, Mr. Lau does not have any negative directorship performance record except the disciplinary action decision. Hence, the Board is of the view that Mr. Lau is suitable to offer himself for re-election as an independent non-executive Director and the chairman of the audit committee of the Company in the fore-coming annual general meeting of the Company.

Save as disclosed above, there is no other information in relation to Mr. Lau that shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter that shall be brought to the attention of the shareholders of the Company and the Stock Exchange in relation to the directorship of Mr. Lau.

On Behalf of the Board of  
**Embry Holdings Limited**  
**Cheng Man Tai**  
Chairman

Hong Kong, 13 May 2021

*As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Cheng Man Tai (Chairman), Ms. Cheng Pik Ho Liza (Chief Executive Officer), Madam Ngok Ming Chu, Mr. Cheng Chuen Chuen and Ms. Lu Qun; and three independent non-executive Directors, namely Mr. Lau Siu Ki, Mr. Lee Kwan Hung and Prof. Lee T. S.*